Intra-Cellular Surges On First Phase III Schizophrenia Data
This article was originally published in Scrip
Executive Summary
Intra-Cellular Therapies saw its share price climb 86.9% to close at a new peak of $48.79 on Sept. 16 after the company reported that ITI-007 showed a potentially differentiated safety profile relative to approved antipsychotic drugs in the first of two Phase III schizophrenia clinical trials.
You may also be interested in...
Surprise Failure for Intra-Cellular Therapies’ Schizophrenia Drug Sends Shares Tumbling
The unexpected failure of a Phase III trial of Intra-Cellular Therapies’ lead product ITI-007 sent shares in the company down by more than 63%.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.
Venture Capital Fundraising Rebounds In Q1 As Mega-Rounds Dominate
Biopharma firms raised $6bn in the first quarter of 2024, the most of any quarter since Q2 2022. But without an increase in the number of companies raising funds, the rebound remains uneven.